NeuroVive Pharmaceutical AB Interim report January – March 2017
Broadened project portfolio
Press releases
NeuroVive invitation to conference call and web cast on in-licensing agreement with Yungjin Pharm
Lund, Sweden, 2 May 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) ("NeuroVive") invites to a conference call and webcast tomorrow, 3 May 2017, at 2:00 pm CEST, to present th ...
NeuroVive in-licenses a genetic mitochondrial disease clinical stage project from Yungjin Pharm
Lund, Sweden and Seoul, Korea, 2 May 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today jointly ann ...
Resolutions from Annual General Meeting in NeuroVive Pharmaceutical AB (publ)
Lund, Sweden, 27 April 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) ("NeuroVive") today on 27 April 2017 held its Annual General Meeting (AGM). A summary of the resolutions ...
NeuroVive Presents Preclinical Findings of NV556 in NASH Showing Confirmatory Anti-fibrotic Effects
Lund, Sweden, 20 April 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical results demonstrating anti-fibrotic effects with NV55 ...
NeuroVive’s lead NASH project to be presented at The International Liver Congress™
Lund, Sweden, April 5, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that an abstract with preclinical data related to t ...
Number of shares and votes in NeuroVive Pharmaceutical AB (publ)
Lund, Sweden, March 31, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced an increase of the number of shares and votes in N ...
NeuroVive Pharmaceutical AB publishes 2016 Annual report
Lund, Sweden, March 23, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that the English version of the Annual report for ...
Notice of Annual General Meeting of Shareholders in NeuroVive Pharmaceutical AB
The Board of Directors of NeuroVive Pharmaceutical AB (publ) has issued a notice to the Annual General Meeting, which is to take place on Thursday, April 27, 2017, at 4 pm at Medicon Village, Scheelev ...
NeuroVive appoints recognized scientific advisors and enters research agreements in NASH and hepatocellular carcinoma
Lund, Sweden, February 22, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced two new research agreements and the appointment ...
NeuroVive Pharmaceutical AB Year End Report January – December 2016
Important steps forward and new research collaborations
NeuroVive’s new generation of sanglifehrin-based compounds demonstrate potent inhibitory effects on human hepatocellular cancer cells
Lund, Sweden, February 2, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, presents preclinical data from a new generation of sanglifehrin- ...